Tumors with BRCA1/2 mutations are often accompanied by homologous recombination deficiency (HRD), and cancer cells with HRD are more sensitive to PARP inhibitors (Rescigno et al., 2018; Chen et al., 2021). The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.